Carnegie Mellon University Neu Base Therapeutics, Inc. Transaction History

Carnegie Mellon University

  • $73.7 Million
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 01, 2023
SELL
$0.13 - $3.05 $116,017 - $2.72 Million
-892,442 Reduced 95.0%
46,970 $87,000
Q4 2021

Feb 11, 2022
BUY
$2.6 - $4.18 $2.44 Million - $3.93 Million
939,412 New
939,412 $2.64 Million

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Carnegie Mellon University Portfolio

Follow Carnegie Mellon University and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carnegie Mellon University, based on Form 13F filings with the SEC.

News

Stay updated on Carnegie Mellon University with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email